These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 19196540

  • 1. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [Abstract] [Full Text] [Related]

  • 2. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 3. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
    Grégoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T.
    Parkinsonism Relat Disord; 2011 May; 17(4):270-6. PubMed ID: 21315648
    [Abstract] [Full Text] [Related]

  • 4. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
    Di Paolo T, Grégoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B.
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
    [Abstract] [Full Text] [Related]

  • 5. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [Abstract] [Full Text] [Related]

  • 6. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ.
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
    Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM.
    Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G, Morissette M, Parent M, Di Paolo T.
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
    Grégoire L, Rassoulpour A, Guidetti P, Samadi P, Bédard PJ, Izzo E, Schwarcz R, Di Paolo T.
    Behav Brain Res; 2008 Jan 25; 186(2):161-7. PubMed ID: 17868931
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.
    Riahi G, Morissette M, Lévesque D, Rouillard C, Samadi P, Parent M, Di Paolo T.
    Neurochem Int; 2012 Dec 25; 61(7):1160-71. PubMed ID: 22940695
    [Abstract] [Full Text] [Related]

  • 17. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
    Bélanger N, Grégoire L, Hadj Tahar A, Bédard PJ.
    Mov Disord; 2003 Dec 25; 18(12):1436-41. PubMed ID: 14673879
    [Abstract] [Full Text] [Related]

  • 18. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
    Bourque M, Grégoire L, Di Paolo T.
    Behav Brain Res; 2018 Jan 30; 337():183-185. PubMed ID: 28917506
    [Abstract] [Full Text] [Related]

  • 19. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov 30; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 20. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN.
    J Pharmacol Exp Ther; 1999 Sep 30; 290(3):1034-40. PubMed ID: 10454475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.